L-arginine and L-citrulline are among the most studied amino acid supplements in cardiovascular nutrition. Both ultimately work through the same pathway — increasing nitric oxide production to dilate blood vessels — yet they differ fundamentally in how reliably they reach their destination. The clinical evidence is substantial but uneven. Here is what it actually shows.

The Nitric Oxide Pathway

Blood pressure regulation is intimately tied to the health and function of the vascular endothelium — the thin layer of cells lining every blood vessel. One of the endothelium's most important jobs is producing nitric oxide (NO), a gas that diffuses into adjacent smooth muscle cells and triggers vasodilation.

The enzyme responsible is endothelial nitric oxide synthase (eNOS). It converts L-arginine into NO and L-citrulline, requiring molecular oxygen and the cofactor tetrahydrobiopterin (BH4) to do so. When eNOS works correctly, NO keeps vessels relaxed and blood pressure in range. When it doesn't — a state called eNOS uncoupling — the enzyme produces superoxide instead of NO, worsening the very oxidative stress that caused the problem.

The practical implication: supplementing either amino acid should, in theory, increase substrate availability for eNOS and support NO production. The question is whether it works in practice — and that is where the clinical data becomes interesting.

eNOS uncoupling is particularly relevant for hypertensive individuals. Cardiovascular risk factors — including diabetes, dyslipidaemia, hypertension itself, smoking, and ageing — all increase vascular oxidative stress and drive eNOS into the uncoupled state. This creates a feedback loop that standard antihypertensive medications do not fully address. Both L-arginine and L-citrulline have been studied partly as a way to break this cycle at the substrate level.

L-Arginine: The Clinical Evidence

The meta-analytic picture

The most comprehensive recent analysis was published in Advances in Nutrition in 2022. Shiraseb and colleagues conducted a systematic review and dose-response meta-analysis of 22 randomised controlled trials (30 effect sizes), searching databases through April 2021.

Subgroup analysis found significant reductions regardless of baseline blood pressure category, sex, health status, or BMI. The dose-response analysis identified ≥4 g/day as the effective threshold for systolic blood pressure reduction, with no significant additional benefit above 9 g/day. DBP reduction was more pronounced in female participants than male.

An earlier meta-analysis by Bai and colleagues (2009) reached similar directional conclusions, confirming the antihypertensive signal was not an artefact of any single analysis.

Ambulatory monitoring in mild hypertension

One RCT assessed L-arginine in mild hypertension using ambulatory blood pressure monitoring — a more rigorous approach than one-off clinic measurements. The study found statistically significant reductions in both SBP and DBP, but only in participants receiving 12 g/day, and the effect was most pronounced during daytime hours. Those on lower doses did not show significant changes.

L-Citrulline: The Clinical Evidence

L-citrulline supplementation has been studied both as a direct intervention and as an indirect arginine-boosting strategy. The evidence base is somewhat more heterogeneous than for arginine, partly because fewer large trials have been conducted and because one influential meta-analysis was subsequently retracted.

Meta-analyses: mixed but directionally consistent

Barkhidarian and colleagues (2019) analysed 8 trials across 10 datasets and found that citrulline could reduce systolic blood pressure, with significant diastolic reductions observed only at doses of ≥6 g/day. This dose threshold has been replicated in other analyses and appears to be a meaningful boundary.

Mirenayat and colleagues (2018), working from a smaller dataset of 5 interventions, found no significant effect on either brachial or aortic blood pressure. This null result highlights the sensitivity of pooled estimates to which studies are included.

Notable RCT: postmenopausal women with elevated BP

A 2022 randomised, placebo-controlled trial enrolled 25 postmenopausal women with elevated blood pressure and assigned them to 10 g/day L-citrulline or placebo for 4 weeks. The citrulline group showed statistically significant improvements in flow-mediated dilation — a direct measure of endothelial function — and a reduction in resting aortic diastolic BP of approximately 2 mmHg, compared to a 2 mmHg increase in the placebo group.

The trial is notable for its population (postmenopausal women are an underrepresented group in cardiovascular supplement research) and its higher dose, which aligns with the ≥6 g threshold from meta-analytic data.

2025 meta-analysis in middle-aged and elderly adults

The most recent pooled analysis (2025) focused specifically on middle-aged and elderly individuals — arguably the population most likely to benefit from interventions targeting vascular stiffness. Fifteen RCTs with 24 datasets and 415 participants were included.

Notably, the analysis found that combined L-citrulline and L-arginine supplementation produced larger effects than either compound alone, consistent with their complementary roles in the NO synthesis pathway.

The Arginine Paradox: Why Citrulline May Be the Smarter Choice

If L-arginine is the substrate for eNOS, why not just supplement with arginine directly? The answer lies in what happens between ingestion and the vascular endothelium — a story of first-pass metabolism that fundamentally limits oral arginine's usefulness at scale.

Normal intracellular L-arginine concentrations in endothelial cells (~100–500 µM) greatly exceed the Michaelis constant of eNOS for arginine (~2–3 µM). In theory, eNOS should already be saturated with substrate and adding more arginine should do nothing. Yet exogenous arginine does increase NO output in many studies — a contradiction called the "arginine paradox."

The paradox likely arises from several converging factors: asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) competitively displacing arginine; arginase overexpression in diseased tissue competing for the same pool; and subcellular compartmentalisation creating local deficiencies near eNOS even when overall cell arginine appears adequate. Whatever the mechanism, the clinical reality is that exogenous arginine can make a difference — the question is how reliably it gets there.

The first-pass metabolism problem

Oral arginine faces substantial presystemic elimination before reaching the circulation:

• Intestinal arginases (types 1 and 2, located in enterocytes) metabolise approximately 40% of ingested arginine on first pass, converting it to L-ornithine and urea
• A further ~15% of systemic arginine is extracted by the liver
• Gut bacteria further degrade a portion of what remains
• In a study of 10 healthy volunteers given 10 g oral arginine, measured bioavailability ranged from 5% to 50% — an average of just 21%, with extreme inter-individual variability

The result: the same dose of arginine can produce dramatically different plasma levels in different people, making predictable dosing extremely difficult.

Why citrulline bypasses this

L-citrulline is not a substrate for intestinal or hepatic arginase. It is absorbed intact, passes directly into systemic circulation without liver extraction, and is converted to arginine in the kidneys — an organ that captures roughly 80% of gut-derived citrulline and releases newly synthesised arginine back into the bloodstream.

A key pharmacokinetic study (Schwedhelm et al., 2008, British Journal of Clinical Pharmacology) confirmed that L-citrulline dose-dependently increased plasma arginine area under the curve more effectively than equivalent doses of L-arginine (P < 0.01). The highest citrulline dose (3 g twice daily) improved the L-arginine/ADMA ratio from 186 ± 8 at baseline to 278 ± 14 — a 49% improvement.

Research in mice has further shown that supplemental citrulline not only raised plasma arginine concentration more than supplemental arginine itself, but also increased arginine flux — the rate at which arginine is produced and used — something arginine supplementation failed to achieve.

Combined Supplementation: Does 1 + 1 > 2?

If arginine provides immediate substrate and citrulline provides sustained substrate replenishment, the logical question is whether combining them amplifies the effect beyond either alone. Mechanistically, this seems plausible for two reasons:

1. They enter the NO synthesis cycle at different points, creating a more continuous substrate supply
2. Co-administered citrulline inhibits arginase allosterically, potentially allowing more ingested arginine to survive first-pass metabolism

Morita and colleagues (2014, Biochemical and Biophysical Research Communications) tested this directly using an oral combination in rabbits. The combined formulation produced a more rapid increase in plasma arginine and a greater enhancement of NO bioavailability — including plasma cGMP concentrations — than either amino acid alone. Blood flow in the central ear artery was also significantly increased by the combination vs control.

The 2025 human meta-analysis in elderly adults corroborated this, finding that combined arginine and citrulline supplementation produced larger BP reductions than citrulline alone. Given the mechanistic logic and the emerging clinical data, combination formulations represent a rational approach — though direct large-scale human RCTs comparing all three conditions remain lacking.

Citrulline Base vs Citrulline Malate: Getting the Dose Right

Citrulline supplements are sold in two main forms: pure L-citrulline and citrulline malate (a compound of L-citrulline and malic acid, typically in a 2:1 citrulline:malate ratio by weight). Most cardiovascular and blood pressure research has used L-citrulline base. Understanding the difference matters for dosing.

A practical note: citrulline malate labels frequently do not disclose the actual citrulline:malate ratio, and some products have been found to contain a 1:1 ratio rather than the stated 2:1, which roughly halves the citrulline content per gram. If you are supplementing for cardiovascular outcomes, verifying the citrulline content per serving matters.

Dosing: What the Evidence Suggests

Safety and Drug Interactions

Both amino acids are generally well-tolerated at therapeutic doses. High-dose L-arginine (above ~10 g) can cause gastrointestinal disturbance — nausea, bloating, diarrhoea — whereas citrulline tends to be better tolerated because it bypasses gut arginase and does not irritate the intestinal mucosa in the same way.

The most clinically significant interactions involve blood pressure medications:

Additional considerations:

• Herpes simplex virus: High-dose L-arginine may trigger HSV reactivation (arginine competes with lysine for cellular uptake and promotes viral replication)
• Asthma and allergies: L-arginine may worsen inflammatory airway conditions
• Pre-surgical: Discontinue arginine supplementation at least 2 weeks before elective surgery
• Pregnancy and breastfeeding: Insufficient safety data — avoid without direct medical supervision

Special Populations

Elderly individuals

Ageing reduces basal arginine levels and appears to impair the renal conversion of citrulline to arginine. After acute citrulline supplementation in older men, plasma arginine returned to baseline within 5–8 hours — a shorter duration than might be expected — suggesting that split dosing or higher total doses may be needed in this population.

Sex differences compound the issue. In older women, L-citrulline supplementation failed to reduce diastolic blood pressure in one trial, while the same intervention worked in older men. The proposed explanation is oestrogen-mediated arginine transport: lower postmenopausal oestrogen levels may reduce arginine uptake into the vasculature, blunting the downstream effect on eNOS activity. The 2022 Texas RCT (10 g/day over 4 weeks in postmenopausal women) did achieve significant effects, suggesting a higher dose threshold may be required in this group.

Diabetic hypertensives

Diabetes creates a particularly hostile environment for eNOS function: hyperglycaemia-driven oxidative stress depletes BH4 and promotes eNOS uncoupling, while insulin resistance reduces PI3K/Akt signalling that would normally upregulate eNOS. Additionally, diabetes upregulates arginase 2, which directly competes with eNOS for the available arginine pool.

This makes the combination of L-arginine and L-citrulline potentially more valuable in diabetic hypertensives than in other groups. L-arginine supplementation has been shown to improve insulin sensitivity and glucose control alongside BP in some trials (6.4–30 g/day), while citrulline's allosteric inhibition of arginase directly counters the diabetes-driven arginase upregulation. That said, specific RCTs in diabetic hypertensives as a defined population remain limited.

The Bottom Line

For context, a 5 mmHg reduction in systolic blood pressure is associated with approximately 9% reduced risk of major cardiovascular events in epidemiological data. The effects seen in arginine and citrulline trials — modest but consistent — fall within a clinically meaningful range, particularly for individuals already pursuing dietary and lifestyle interventions.

Both compounds are best understood as adjuncts to established cardiovascular health strategies, not replacements. The quality of evidence is improving — but the most honest summary remains: promising, mechanistically sound, and in need of larger, better-standardised trials before strong clinical recommendations can be made.

Key References

1. Shiraseb F et al. Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose–Response Meta-analysis of Randomized Clinical Trials. Adv Nutr. 2022;13(4):1226–1242. PMID 34967840
2. Schulman SP et al. L-arginine therapy in acute myocardial infarction: the VINTAGE MI randomized clinical trial. JAMA. 2006;295(1):58–64. PMID 16391217
3. Schwedhelm E et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51–59. PMID 17662090
4. Barkhidarian B et al. Effects of L-citrulline supplementation on blood pressure: A systematic review and meta-analysis. Avicenna J Phytomed. 2019. PMC6369322
5. Mirenayat MS et al. Effect of L-Citrulline supplementation on blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep. 2018. PMID 30284051
6. Morita M et al. Oral supplementation with a combination of L-citrulline and L-arginine rapidly increases plasma L-arginine concentration and enhances NO bioavailability. Biochem Biophys Res Commun. 2014;521(3):736–741. PMID 25445598
7. Khalaf D et al. The Effects of Oral L-Arginine and L-Citrulline Supplementation on Blood Pressure. Nutrients. 2019;11(7):1679. PMC6683098
8. eNOS uncoupling and endothelial dysfunction review. Cell Mol Biol Lett. 2023. DOI 10.1186/s11658-023-00423-2
9. Morris SM Jr et al. Supplemental Citrulline Is More Efficient Than Arginine in Increasing Systemic Arginine Availability in Mice. PMC5368575
10. 2025 Meta-analysis in middle-aged and elderly adults. ScienceDirect 2025